Kiniksa Pharmaceuticals International, plc

Good day, and thank you for standing by. Welcome to the Knicks Pharmaceuticals third quarter conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that session, you will need to press star 1 on your telephone. If you require any assistance during the call, please press star 0. I would now like to hand the conference over to your speaker today, Ms. Rachel Frank. Ms. Frank, you may begin.

Thank you, Operator. Good morning, everyone, and thank you for joining Connexta's call to discuss our third quarter 2021 financial results and our recent corporate and pipeline activity. A press release highlighting these results can be found on our website under the Investors in Media section. As for the agenda, our Chief Executive Officer, Sanj Kay Patel, will start with an introduction. Ross Mote, our head of commercial, will provide an update on the Arculus commercial launch. Evan Tesari, Connexa's chief business officer, will follow with a brief pipeline review. Mark Ragosa, our chief financial officer, will review our third quarter 2021 financial results. And finally, Sanz will return for closing remarks and to kick off the Q&A session for which John Paolini, our chief medical officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide as well as under the caption, Risk Factors, contained in our SEC filing. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I will turn it over to Sanj.

Thanks, Rachel. Good morning, everyone. I'm happy to review our third quarter 2021 results today. We continue to make tremendous progress in bringing Arclist to patients in need. And we're also executing across our portfolio of clinical stage product candidates. I'm delighted to report that net revenue for Arclist for the third quarter of 2021 was $12.1 million. As expected, recurrent pericarditis was the major growth driver for the Arclist Q3 sales. Ross will cover our commercial performance in more detail in a moment. We are very pleased with the implementation of our targeted commercial strategy. This includes broad physician and patient adoption and the viable reimbursement conditions. These core elements are what's driving recurrent pericarditis sales and underscore the significant need for Arclist. Additionally, we remain focused on building the maximum value across our portfolio of clinical stage product candidates, and these are Mavilimumab, Vixilimumab, and KPL404, which is our CD40 program. We continue to expect data in the first quarter of 2022 from our phase three trial of MAVERI in COVID-19 related ARDS. And Eben will highlight the potential opportunity in this patient population a little later. We continue to be energized by our progress across the entire portfolio. And we believe that we're well positioned for longer term growth. I'll now turn it over to Ross to discuss our commercial performance in more detail. Ross.